Proposal to list urology and continence medical devices supplied by Reynard Health Supplies Limited & Culpan Distributors Limited

Hospital devices

Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule, effective 1 November 2019, through listing agreements with Reynard and Culpan.

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule, effective 1 November 2019, through listing agreements with:

  • Culpan Distributors Limited (“Culpan”) for urology and continence products; and
  • Reynard Health Supplies Limited (“Reynard”) for continence products.

Consultation closes at 4pm on Thursday, 19 September 2019 and feedback can be emailed to josh.wiles@pharmac.govt.nz.

What would the effect be?

From 1 November 2019, Culpan’s and Reynard’s urology and continence products would be listed on the Pharmaceutical Schedule, under national agreements for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreements”).

The Agreements would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of urology and continence products.

The Agreements would supersede any existing DHB contracts with Culpan and Reynard for the urology and continence products included in the Agreements.  Any urology or continence products listed in the Agreements and purchased by the DHB, would be at the price, and the terms and conditions stated in the Agreements, effective from the date of listing on the Pharmaceutical Schedule.

As part of the Agreements, Culpan and Reynard would provide training and education that would be tailored to the needs of the individual DHBs.

Who we think will be interested

  • Suppliers and Wholesalers
  • DHB Staff
    • Clinical staff in a range of inpatient, outpatient and community settings where urology, and continence products are used
    • Procurement and supply chain personnel.

About urology and continence products

Urology and continence products are used in hospital and community setting, from short to long-term use.

Urology products include urethral, suprapubic and sheath catheters, bags and accessories for the management of urinary drainage.

Continence Products include a range of devices to help manage bowel and bladder control problems, including pads, collection systems and skin protection products, as well as nappies for infants for use while they are in hospital.

Why we’re proposing this

In May 2018, PHARMAC issued a Request for Proposals (“RFP”) for the supply of urology, ostomy and continence products.

The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC is working with a range of suppliers to seek provisional agreements and this proposal is the latest to arise from that process.  We expect to consult on further proposed agreements in the urology, ostomy and continence categories over the coming months.

Details about our proposal

PHARMAC has entered into provisional agreements with Culpan and Reynard for a range of urology and continence products.  Pricing has been made available to appropriate DHB personnel.

This proposal would result in listing 318 urology and continence products supplied by Culpan and Reynard, on the Pharmaceutical Schedule

The brands included in the Agreements are:

Culpan

Reynard

Continence (202 products)

  • ProFem

Continence (4 products)

  • Reynard

Urology (112 products)

  • Colopast
  • Folysil
  • Lofric
  • X-Flow
 

To provide feedback

Send us an email: josh.wiles@pharmac.govt.nz by 4pm on Thursday, 19 September 2019.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.